anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Patients in Group S underwent a procedure where a high-frequency linear ultrasound probe (Clarius, 205-2980 Virtual Way, Vancouver, BC, Canada V5M 4X3 MyLabFive; Esaote Europe BV Philipsweg 1 6227 AJ, Maastricht, the Netherlands) was positioned on the transverse plane, specifically on the fifth spinous process. The probe was then moved downwards to visualize the first and second median sacral crest. Next, the transducer was placed 3-4 cm laterally to the second medial sacral crest in order to visualize the intermediate sacral crest. In the interfascial plane, a total of 20 mL of local anesthetic solution (comprised of 10 mL bupivacaine 0.5%, 5 mL lidocaine 2%, and 5 mL normal saline) was injected between the erector spinae muscles and the intermediate sacral crest. The same procedure was performed on the contralateral side.
PURPOSE: To assess the experience and perceived added value of an e-Health application during the physical therapy treatment of patients with temporomandibular disorders (TMD).
MATERIALS AND METHODS: A mixed-methods study including semi-structured interviews was performed with orofacial physical therapists (OPTs) and with TMD patients regarding their experience using an e-Health application, Physitrack. The modified telemedicine satisfaction and usefulness questionnaire and pain intensity score before and after treatment were collected from the patients.
RESULTS: Ten OPTs, of which nine actively used Physitrack, described that the e-Health application can help to provide personalised care to patients with TMD, due to the satisfying content, user-friendliness, accessibility, efficiency, and ability to motivate patients. Ten patients, of which nine ended up using Physitrack, felt that shared decision-making was very important. These patients were positive towards the application as it was clear, convenient, and efficient, it helped with reassurance and adherence to the exercises and overall increased self-efficacy. This was mostly built on their experience with exercise videos, as this feature was most used. None of the OPTs or patients used all features of Physitrack. The overall satisfaction of Physitrack based on the telemedicine satisfaction and usefulness questionnaire (TSUQ) was 20.5 ± 4.0 and all patients (100%) showed a clinically relevant reduction of TMD pain (more than 2 points and minimally 30% difference).
CONCLUSION: OPTs and patients with TMD shared the idea that exercise videos are of added value on top of usual physical therapy care for TMD complaints, which could be delivered through e-Health.Implications for RehabilitationPhysical therapists and patients with temporomandibular disorders do not use all features of the e-Health application Physitrack in a clinical setting.Exercise videos were the most often used feature and seen as most valuable by physical therapists and patients.Based on a small number of participants, e-Health applications such as Physitrack may be perceived as a valuable addition to the usual care, though this would need verification by a study designed to evaluate the therapeutic effect (e.g., a randomised clinical trial).
Optical characterization mode of CAD EYE® (CAD EYE® ON) in BLI mode should be activated for the evaluation of CAD EYE® optical characterization, in hyperplastic or neoplastic polyps, as well as the level of characterization (graduated from 1 to 3). The evaluation of the CAD EYE® should also be recorded by the endoscopist in the exam room who is not performing the colonoscopy, on its own record sheet. The iconographic record of evaluated polyps in WLI and BLI modes and the evaluation video using CAD EYE® in BLI characterization mode should be done.
PURPOSE: A non-glossy cosmetic composition for lip make-up or lip care is provided to ensure moisturization effect over conventional cosmetic composition. CONSTITUTION: A non-glossy cosmetic composition for lip make-up or lip care contains a copolymer comprising two or more silicon derivative ingredients and a hydrocarbon compounds. The copolymer is denoted by chemical formula 1, (H3C)3Si-O-(S1-S2 ~-Sn)-Si(CH3)3. In chemical formula 1, S is silicon derivative segment and Sn is other silicon derivative segment. The copolymer is contained in 0.1-50 weight% based on total weight. The hydrocarbon compound is contained in 0.1-40 weight% based on total weight.
Six-week virtual, group nutrition education series using the HomeStyles-2 experimental curriculum administered through SNAP-Ed. This curriculum addresses factors affecting school-aged children's health and nutritional status: inadequate intake of fruits and vegetables, infrequent family meals, excessive consumption of sugar-sweetened beverages, large portion sizes, and irregular breakfast consumption.
All participants will receive the same drug conditions, but the order in which the participants receive the drug conditions will be different across participants. Thus, comparisons of the drug conditions on mood and choice will be compared within-subjects (e.g., between drug and placebo). During the caffeine maintenance condition, participants will ingest 200 mg of caffeine orally in capsules three times daily.
Immune checkpoint molecules play pivotal roles in the regulation of immune homeostasis. Disruption of the immune checkpoints causes autoimmune/inflammatory as well as malignant disorders. Over the past few years, the immune checkpoint molecules with inhibitory function emerged as potential therapeutic targets in oncological conditions. The inhibition of the function of these molecules by using immune checkpoint inhibitors (ICIs) has brought paradigmatic changes in cancer therapy due to their remarkable clinical benefits, not only in improving the quality of life but also in prolonging the survival time of cancer patients. Unfortunately, the ICIs soon turned out to be a "double-edged sword" as the use of ICIs caused multiple immune-related adverse effects (irAEs). The development of inflammatory neuropathies such as Guillain-Barré syndrome (GBS) and Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) as the secondary effects of immunotherapy appeared very challenging as these conditions result in significant and often permanent disability. The underlying mechanism(s) through which ICIs trigger inflammatory neuropathies are currently not known. Compelling evidence suggests autoimmune reaction and/or inflammation as the independent risk mechanism of inflammatory neuropathies. There is a lack of understanding as to whether prior exposure to the risk factors of inflammatory neuropathies, the presence of germline genetic variants in immune function-related genes, genetic variations within immune checkpoint molecules, the existence of autoantibodies, and activated/memory T cells act as determining factors for ICI-induced inflammatory neuropathies. Herein, we highlight the available pieces of evidence, discuss the mechanistic basis, and propose a few testable hypotheses on inflammatory neuropathies as irAEs of immunotherapy.
This is an open label phase 2 randomized study in which eligible AML patients will be randomly assigned (1:1) to receive either the FDA label-approved regimen of 28-day Venetoclax + Azacitidine (Arm A) or the 14-day regimen of Venetoclax + Azacitidine (Arm B). Newly diagnosed acute myeloid leukemia (AML) patients ≥ 60 years will be enrolled.
BACKGROUND: The use of antiretrovirals has increased the survival of People Living with HIV/AIDS (PLWHA), resulting in an aging population and a rise in the incidence of sarcopenia. The lack of uniformity among the prevalences found in studies may be associated with the use of different diagnostic criteria, highlighting the need for local studies to determine the prevalence of sarcopenia.
METHODS: Cross-sectional study to estimate the prevalence and associated factors of sarcopenia using the revised criteria of the European Working Group on Sarcopenia in Older People (EWGSOP2). This study included PLWHA of both sexes, aged 40 years or older, who were treated at the infectious disease outpatient clinic of a tertiary hospital from 2019 to 2021. Muscle mass was quantified through electrical bioimpedance, using resistance and reactance to calculate appendicular lean mass (ALM) in kg/m². Muscle strength, measured in kg, was assessed using a manual dynamometer, and muscle function was evaluated using the gait speed test (m/s). Numerical variables were analyzed using measures of central tendency and dispersion. The chi-square test was used to assess associations in categorical variables. Odds ratios (OR) and 95% Confidence Intervals (CI) were calculated to evaluate the strength of associations.
RESULTS: Among the 218 PLWHA, the prevalence of sarcopenia was 8.7% (95% CI: 5.6 to 13.3). The mean age of the study population was 51.8 ± 8.3 years; 53.7% were male, 72.9% were brown/Black, 97.7% reported not using illicit drugs, and 24.8% were classified as obese. Multivariate analysis showed that the time since HIV diagnosis (P = 0.022) and the use of illicit drugs were associated with the diagnosis of sarcopenia.
CONCLUSION: The prevalence of sarcopenia using the EWGSOP2 criteria was low. People with a longer duration of HIV infection and those using illicit drugs were more likely to develop sarcopenia.
People aged 60 and over who had refused to participate in fall prevention workshops will be included. They will have semi-structured interviews.
NEW MATERIAL:Polysaccharide RDP substance. Not permeating a dialysis membrane. Insoluble in alcohol, acetone, benzene, etc. Soluble in water. 1wt% aqueous solution is neutral. Containing <=5wt% inorganic substances. Positive in Molish reaction, anthrone sulfuric acid reaction, tryptophan sulfuric acid reaction, etc. Negative in biuret reaction, ninhydrin reaction, Lowry- folin reaction, etc. Having alpha-1,6-glucoside bond as a main skeleton, and alpha-1,4 glucoside bond. USE:An antitumor agent, immune adjusting agent, preventive and remedy for infectious diseases. PREPARATION:Rice bran is crushed finely, 5-10 times as much distilled water is added to it, which is treated with hot water by the use of a pressure container at 0-3.0kg/cm<2> at 100-140 deg.C for 1-5hr, to give an extracted solution. A polar organic solvent or a salting-out agent is added to it, the prepared precipitate is collected, dissolved in water, and protein is removed from it, to give polysaccharide RDP substance.
Defining HLA mismatch at the molecular compared with the antigen level has been shown to be superior in predicting alloimmune responses, although data from across different patient populations are lacking. Using HLA-Matchmaker, HLA-EMMA and PIRCHE-II, this study reports on the association between molecular mismatch (MolMM) and de novo donor-specific antibody (dnDSA) in an ethnically diverse kidney transplant population receiving a steroid-sparing immunosuppression protocol. Of the 419 patients, 51 (12.2%) patients had dnDSA. De novo DSA were seen more frequently with males, primary transplants, patients receiving tacrolimus monotherapy, and unfavorably HLA-matched transplants. There was a strong correlation between MolMM load and antigen mismatch, although significant variation of MolMM load existed at each antigen mismatch. MolMM loads differed significantly by recipient ethnicity, although ethnicity alone was not associated with dnDSA. On multivariate analysis, increasing MolMM loads associated with dnDSA, whereas antigen mismatch did not. De novo DSA against 8 specific epitopes occurred at high frequency; of the 51 patients, 47 (92.1%) patients with dnDSA underwent a pretreatment biopsy, with 21 (44.7%) having evidence of alloimmune injury. MolMM has higher specificity than antigen mismatching at identifying recipients who are at low risk of dnDSA while receiving minimalist immunosuppression. Immunogenicity consideration is important, with more work needed on identification, especially across different ethnic groups.
Death from metastatic cancer is a common cause of death, accounting for 80-90% of cancer deaths. The classic thought process is that metastatic disease represents the continuum such that known metastatic disease is an inevitable harbinger for subsequent metastatic disease. However, it has been reported that a subset of patients with limited volume metastatic disease may have a better prognosis if given aggressive therapy. This group of patients has become known as "oligometastatic". These patients are potentially curable with stereotactic radiosurgery (SRS) or stereotactic radiotherapy (SRT) (collectively referred to as stereotactic body radiotherapy or SBRT) to the metastatic disease sites in combination with standard curative therapy to the primary site. Patients in this study receive SRS/SBRT to all sites of oligometastatic disease.
One aspect of the invention relates to 1,8-diarylnaphthalene compounds. In certain embodiments, a compound of the invention is an N-oxide of a 1,8-diarylnaphthalene. In certain embodiments, the aryl group is an optionally substituted acridyl group. In certain embodiments, a compound of the invention is a single steroisomer. In certain embodiments, a compound of the invention is a single enantiomer. Another aspect of the present invention relates to a method of detecting the presence of an analyte in a sample by monitoring the fluorescence of a compound of the invention in a sample. In certain embodiments, the analyte is a metal ion. Another aspect of the present invention relates to a method of determining the enantiomeric purity of an analyte by monitoring the fluorescence of a compound of the invention in the presence of the analyte. In certain embodiments, the analyte is a compound that is capable of hydrogen bonding.
PROBLEM TO BE SOLVED: To obtain the lamellar structure containing a new sterol fatty acid ester as an essential ingredient, having a moisture-retaining ability excellent in a corneous water content-retaining ability, and useful as a humectant, a cosmetic, and a skin disease-treating agent caused by dryness. SOLUTION: This lamellar structure contains a sterol fatty acid ester as an essential ingredient. The sterol fatty acid ester includes a cholesteryl branched fatty acid ester, a phytosteryl branched fatty acid ester, cholesteryl lanolin fatty acid ester, a soft cholesteryl lanolin fatty acid ester, a hard cholesterol lanolin fatty acid ester and a cholesteryl non-hydroxylanolin fatty acid, and is produced by a method comprising the esterification of a sterol such as cholesterol with a fatty acid, etc. The lamellar structure is obtained by physically stirring and dispersing a mixture comprising approximately 0.1-99 pts.wt. of a sterol fatty acid ester and approximately 99.9-1 pts.wt. of water.
UNLABELLED: In this randomized, placebo-controlled cross-over trial we aimed to investigate if radon spa therapy exerts more pain relief than exposure to warm water alone. In addition, immunological parameters were assessed in both treatment groups. In the RAD-ON02 trial, 116 patients suffering from musculoskeletal disorders (MSDs) received either serial radon spa or solely warm water baths. Pain intensity was assessed by determination of different pain parameters on a visual analogue scale and by pressure point dolorimetry at baseline and at weeks 4, 12 and 24. The longitudinal immune status of the patients was analyzed by a flow cytometry-based assay from peripheral blood at the time points of pain assessments. There were no side effects attributable to radon exposure observed. However, radon spa was superior to warm water applications at week 4 in terms of pain reduction. Pain and morning stiffness at the time of assessment were significantly reduced after radon spa (p<0.001, p<0.01) but not after warm water baths. The dolorimetry resulted in a significantly higher exerted pressure strength in patients after radon spa (p<0.001), but not after warm water applications. During the long-term follow-up, both treatment modalities reduced pain to a similar degree and pain modulation was not distorted by the participants' intake of analgesics. No significant changes in the immune status attributable specifically to radon were found, even though the increase in regulatory T cell counts occurs earlier after radon baths than after sole warm water baths and a higher level of significance is reached after radon spa at week 24. Serial radon spa has additive pain-relieving effects. The immunological parameters assessed in our study appear not to be directly linked to the pain reduction caused by radon exposure, at least in MSD patients with predominantly degenerative diseases.
CLINICAL TRIAL REGISTRATION: https://www.clinicaltrialsregister.eu/ctr-search/search?query=rad-on02, identifier 2016-002085-31; https://drks.de/search/de/trial, identifier DRKS00016019.
Layered implantable sensors are described herein. Layered sensors described herein may include one or more analyte sensing populations. The one or more analyte sensing populations may detect different analytes, or different concentrations of the same analyte, for example. The layered sensors may include a reference population. The reference population may, or may not, be analyte sensing. As described herein, the first sensing population may be separated from a second sensing population (and/or a reference population) by a passive layer.
The present invention develops a novel technology that is able to easily perform antigen-specific CTL induction for any given antigen. The present invention provides a cytotoxic T cell inducing composition containing: an anti-CD28 antibody; a solid support body at which the anti-CD28 antibody has been solid-phased; and a soluble peptide that can bond to an MHC class I molecule. In the cytotoxic T cell inducing composition, there are cases of the soluble peptide that can bond to an MHC class I molecule being presented as an antigen by means of an HLA compliant HLA complex of the patient and being recognized by the cytotoxic T cells. The present invention provides a tumor treatment drug composition. The tumor treatment drug composition contains the cytotoxic T cell inducing composition, the soluble peptide that can bond to an MHC class I molecule contains a portion of the amino acid sequence of a specific antigen protein of tumor cells, and the cytotoxic T cells recognize the tumor cells. The specific antigen protein of the tumor cells can be WT-1.
The invention belongs to the field of medicines, and particularly relates to a medicine composition for treating diarrhea as well as a preparation method and application thereof. The technical problem to be solved by the invention is to provide the new medicine composition. The new medicine composition comprises the following medicinal raw materials in parts by weight; 1-3 parts of ephedra, 1-4 parts of radix peucedani and 2.5-4.5 parts of semen plantaginis. The purpose of treating or improving diarrhea can be realized by the method. For the convenience of application and the simpleness and convenience of preparations, the medicine composition is prepared into decoction for use by an inventor. The medicine composition is used for clearing damp and stopping diarrhea, is suitable for treatment of diarrhea of children aged 0 to 12 years and can also be taken by adults. The medicine composition can be used for treating various types of diarrheas and is particularly suitable for gastrointestinal type cold and simple diarrhea and chronic diarrhea of children; and more than 10 years of clinical application observation proves that more than 300 of diarrhea patents are treated, and the recovery rate is above 95%. The medicine composition can also be used for treating cold and relieving a cough, treats more than 200 of patients suffering from cold and cold and has the recovery rate of above 85%.
BACKGROUND: Alpha-1 antitrypsin deficiency (AATD) is an inherited disease, the common variant caused by a Pi*Z mutation in the SERPINA1 gene. Pi*Z AAT increases the risk of pulmonary emphysema and liver disease. Berberine (BBR) is a nature dietary supplement and herbal remedy. Emerging evidence revealed that BBR has remarkable liver-protective properties against various liver diseases. In the present study, we investigated the therapeutic effects and toxicities of BBR in Pi*Z hepatocytes and Pi*Z transgenic mice.
METHODS: Huh7.5 and Huh7.5Z (which carries the Pi*Z mutation) cells were treated with different concentrations of BBR for 48 hours. MTT was performed for cell viability assay. Intracellular AAT levels were evaluated by western blot. In vivo studies were carried out in wild type, native phenotype AAT (Pi*M), and Pi*Z AAT transgenic mice. Mice were treated with 50 mg/kg/day of BBR or solvent only by oral administration for 30 days. Western blot and liver histopathological examinations were performed to evaluate therapeutic benefits and liver toxicity of BBR.
RESULTS: BBR reduced intracellular AAT levels in Huh7.5Z cells, meanwhile, no Pi*Z-specific toxicity was observed. However, BBR did not reduce liver AAT load but significantly potentiated liver inflammation and fibrosis accompanying the activation of unfolded protein response and mTOR in Pi*Z mice, but not in wild type and Pi*M mice.
CONCLUSIONS: BBR exacerbated liver inflammation and fibrosis specifically in Pi*Z mice. This adverse effect may be associated with the activation of unfolded protein response and mTOR. This study implicates that BBR should be avoided by AATD patients.
<P>PROBLEM TO BE SOLVED: To provide a cosmetic formulated with a titanium oxide composition having high iridescent color, concretely a new titanium composition produced by coating a flaky substrate with a titanium composition and peeling the applied titanium composition and a cosmetic formulated with the new titanium composition.  <P>SOLUTION: A titanium oxide having high iridescent color is used as the cosmetic. The titanium oxide is composed of a peeled composition produced by forming a coating layer of a titanium composition having a thickness of 0.05-0.6μm on the surface of a flaky substrate having a size of 50-800μm and peeling the coating layer of the titanium composition to form the coating layer composition. The flaky substrate is selected from natural mica, synthetic mica, glass flake, silica flake, alumina flake and barium sulfate and contains titanium oxide and/or titanium hydroxide in an amount of 70-99 wt.%. The cosmetic further contains 1-20 wt.% reinforcing agent composed of the oxide or hydroxide of one or more metals selected from iron, zinc, cobalt, nickel, lithium, sodium, bismuth, tungsten, tin, silica, alumina and zirconium.  <P>COPYRIGHT: (C)2004,JPO
N-(Substituted benzyl)-8-hydroxy- 1,6-naphthyridine-7-carboxamides are inhibitors of HIV integrase and inhibitors of HIV replication. The naphthyridine carboxamides are of Formula (I): (I),wherein R1', R2' and R3' are defined herein. The compounds are useful in the prevention and treatment of infection by HIV and in the prevention, delay in the onset, and treatment of AIDS. The compounds are employed against HIV infection and AIDS as compounds per se or in the form of pharmaceutically acceptable salts. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of preventing, treating or delaying the onset of AIDS and methods of preventing or treating infection by HIV are described.